Effects of olmesartan vs irbesartan on metabolic parameters and visfatin in hypertensive obese women

European Review for Medical and Pharmacological Sciences

Volumn 14, Issue 9, 2010, Pages 759-763

  De Luis, Daniel A ^a   Conde, R ^a   Gonzalez Sagrado, M ^a   Aller, R ^a   Izaola, O ^a   Perez Castrillon, J L ^a   Romero, E ^a   Castro, M J ^a  

^a UNIVERSITY OF VALLADOLID   (Spain)

Author keywords

Angiotensin blockers; Hypertension; Insulin resistance; Obese; Visfatin; Women

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; IRBESARTAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OLMESARTAN; TRIACYLGLYCEROL;

ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; HUMAN; HYPERTENSION; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; OBESITY; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; BIPHENYL COMPOUNDS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; BODY WEIGHT; CHOLESTEROL; CYTOKINES; FEMALE; HUMANS; HYPERTENSION; IMIDAZOLES; INSULIN; MIDDLE AGED; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OBESITY; PROSPECTIVE STUDIES; SPAIN; TETRAZOLES; TIME FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 78649417124     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. FANTUZZI G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol, 2005: 115; 911-919.
2. MEIER U, GRESSNER AM. Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin and resistin. Clin Chemistry 2004; 50: 1511-1525.
3. FRAYN KN. Subcutaneous and visceral adipose tissue their relation to metabolic syndrome. Endocr Rev 2000; 21: 697-738.
4. FUKUHARA A, MATSUDA M, NISHIZAWA M, SEGAWA K, TANAKA M, KISHIMOTO K, MATSUKI Y, MURAKAMI M, ICHISAKA T, MURAKAMI H, WATANABE E, TAKAGI T, AKIYOSHI M, OHTSUBO T, KIHARA S, YAMASHITA S, MAKISHIMA M, FUNAHASHI T, YAMANAKA S, HIRAMATSU R, MATSUZAWA Y, SHIMOMURA I. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 307: 426-430. (Pubitemid 40139988)
5. CHOI KC, RYU OH, LEE KW, KIM HY, SEO JA, KIM SG, KIM NH, CHOI DS, BAIK SH, CHOI KM. Effect of PPAR-alpha and -gamma agonist on the expression of visfatin, adiponectin, and TNF-alpha in visceral fat of OLETF rats. Biochem Biophys Res Commun 2005; 336; 747-753.
6. HAIDER DG, HAIDER DG, MITTERMAYER F, SCHALLER G, ARTWOHL M, BAUMGARTNER-PARZER SM, PRAGER G, RODEN M, WOLZT M. Free fatty acids normalize a rosiglitazone-induced visfatin release. Am J Physiol Endocrinol Metab 2006: 291: E885-880.
7. STORKA A, VOJTASSAKOVA E, MUELLER M, KAPIOTIS S, HAIDER DG, JUNGBAUER A, WOLZT M. Angiotensin inhibition stimulates PPARgamma and the release of visfatin. Eur J Clin Invest 2008; 38: 820-826.
8. BERNDT J, KLÖTING N, KRALISCH S, KOVACS P, FASSHAUER M, SCHON M, STUMVOLL M, BLÜHER M. Plasma visfatin concentrations and fat depot specific RNA expresion in humans. Diabetes 2005; 54: 2911-2916.
9. WORLD HEALTH ORGANIZATION-INTERNATIONAL SOCIETY OF HYPERTENSION. Guidelines for the management of hypertension. J Hypertens 1999; 17: 151-183.
10. MATTHEWS DR, HOSKER JP, RUDENSKI AS, NAYLOR BA, TREACHER DF, TURNER RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-414.
11. FURUHASHI M, URA N, TAKIZAWA H, YOSHIDA D, MONIWA N, MURAKAMI H, HIGASHIURA K, SHIMAMOTO K. Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity. J Hypertens 2004; 22: 1977-1982. (Pubitemid 39336681)
12. FURUYA R, ODAMAKI M, KUGAMAI H, HISHIDA A. Impact of angiotensin II receptor blocker on plasma levels of adiponectin and advanced oxidation protein products in peritoneal dialysis patients. Blood Purif 2006; 24: 445-450.
13. FURUHASHI M, URA N, HIGASHIURA K, MURAKAMI H, TANAKA M, MONIWA N, YOSHIDA D, SHIMAMOTO K. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003; 42: 76-81.
14. YENICESU M, YILMAZ MI, CAGLAR K, SONMEZ A, EYILETEN T, ACIKEL C, KILIC S, BINGOL N, BINGOL S, VURAL A. Blockade of the renin-angiotensin system increases plasma adiponectin levels in type-2 diabetic patients with proteinuria. Nephron Clin Pract 2005; 99: c115-c121.
15. RAN J, HIRANO T, ADACHI M. Angiotensin II type 1 receptor blocker ameliorates overproduction and accumulation of triglyceride in the liver of Zucker fatty rats. Am J Physiol Endocrinol Metab 2004; 287: E227-E232.
16. HAMMARSTEDT A, PIHLAJAMAKI J, ROTTER SOPASAKIS V, GOGG S, IANSON PA, LAAKSO M. Visfatin is an adipokine, but it is not regulated by thiazolinediones. J ClinEndocrinol Metab 2006; 91: 1181-1184.
17. ZAHORSKA-MARKIEWICZ B, OLSZANECKA-GUNIANOWICZ M, JANOWSKA J, KOCELAK P, SEMIK-GRABACZYK E, HOLECKI M. Sreum concentration of visfatin in obese women. Metabolism 2007; 56: 1131-1134.
18. DE LUIS DA, GONZALEZ SAGRADO M, CONDE R, ALLER R, IZAOLA O, ROMERO E. Effect of a hypocaloric diet on serum visfatin in obese non-diabetic patients. Nutrition 2008; 24: 517-521.
19. COATS AJ. Ethical authorship and publishing. Int J Cardiol 2009; 131: 149-150.